8-K: FOXO Technologies Inc. Restates Financials Due to Warrant Accounting Errors

FOXO Technologies Inc. announced it will restate its financial statements for the three and nine months ended September 30, 2023, due to errors in accounting for common stock warrants.

Summary

• FOXO Technologies Inc. has identified errors in its previously issued unaudited financial statements for the three and nine months ended September 30, 2023.
• The errors relate to the accounting for outstanding common stock warrants, specifically the down round provision features of warrants assumed in a prior business combination.
• A triggering event occurred on September 19, 2023, due to the issuance of rights to receive shares under a Shares for Services Agreement, which required a reduction in the per share exercise price and an increase in the number of outstanding warrants.
• The company did not record a deemed dividend of approximately $0.9 million resulting from the trigger of the down round provision in the original financial statements.
• The restatement will correct the understatement of the deemed dividend, the number of outstanding warrants (from 25,868 to 2,007,848), and the overstatement of the exercise price (from $62.10 to $0.80 per share).
• The correction of these errors did not impact assets, liabilities, total stockholders deficit, total cash flows, net loss or comprehensive loss, but it did increase the net loss per share.

Sentiment

Score: 3

Explanation: The document indicates a significant accounting error requiring a restatement, which is a negative development. While the company is taking steps to correct the issue, the overall sentiment is negative due to the potential impact on investor confidence and the company's stock price.

Positives

• The company has identified and is correcting the accounting errors.
• The restatement does not impact assets, liabilities, total stockholders deficit, total cash flows, net loss or comprehensive loss.

Negatives

• The company's previously issued financial statements for the three and nine months ended September 30, 2023, were inaccurate.
• A deemed dividend of $0.9 million was not recorded, leading to an understatement of net loss to common stockholders.
• The number of outstanding warrants was significantly understated, and the exercise price was overstated.
• The restatement will result in a higher net loss per share for the affected periods.

Risks

• The restatement of financial statements could negatively impact investor confidence.
• The company's stock price may suffer as a result of the restatement and any subsequent determinations from this process.
• There is a risk of further adjustments to the company's previously issued financial statements.
• The company faces potential scrutiny from governmental or regulatory bodies.

Future Outlook

The company plans to file an amended Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, as soon as practicable. The company cautions not to place undue reliance on forward-looking statements.

Management Comments

• The Board concluded that the previously issued unaudited condensed consolidated financial statements should no longer be relied upon.
• The Board and the Company's management have discussed the matters in this report with its independent registered public accounting firm.

Industry Context

This announcement highlights the complexities of accounting for warrants, particularly those with down round provisions, which is a common issue for companies that have undergone business combinations or have complex capital structures. The restatement underscores the importance of accurate financial reporting and adherence to accounting standards.

Comparison to Industry Standards

• The need to restate financials due to warrant accounting errors is not uncommon, particularly for companies with complex financial instruments.
• Other companies, such as those in the biotech or technology sectors, have faced similar issues related to the valuation and accounting of warrants and other equity-linked instruments.
• The specific accounting standards referenced, such as ASU 2017-11 and ASU 2021-04, are widely applicable, and companies are expected to adhere to these guidelines.
• The restatement process itself is a standard procedure when errors are identified, and the company's actions are in line with industry best practices for correcting financial misstatements.

Stakeholder Impact

• Shareholders will be impacted by the restatement and potential stock price volatility.
• Employees may be affected by the uncertainty surrounding the company's financial health.
• Creditors may reassess their risk exposure to the company.

Next Steps

• The company plans to file an amended Quarterly Report on Form 10-Q for the quarter ended September 30, 2023.

Key Dates

Keywords

financial restatement, warrant accounting, deemed dividend, down round provision, financial statements, accounting errors, Form 8-K, FOXO Technologies